Moderna Q2 2025 Financial Results and Business Updates

SEC Filing 8-K (0001682852-25-000041)

Moderna, Inc. reported its financial results for the second quarter of 2025, with revenues of $142 million, a 41% decrease from the same period in 2024. The company announced a GAAP net loss of $(0.8) billion and a GAAP EPS of $(2.13). Moderna updated its 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily due to the timing of deliveries for contracted revenue into the first quarter of 2026. The company also improved its 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion. Moderna reiterated its 2025 expected year-end cash balance of approximately $6 billion. Recent progress includes three U.S. FDA approvals and positive Phase 3 efficacy results for its seasonal influenza vaccine.